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angulated lesion (1st DES vs. 2nd DES: 12.3% vs. 29.2%, p < 0.001),
burr-to-artery ratio (0.62 vs. 0.59, p < 0.001), and IVUS use (42.8% vs. 81.7%, p
< 0.001). In all patients, no signiﬁcant differences were observed between 2 groups
in the restenosis and TLR rates (21.2 vs. 14.2%, p ¼ 0.12 and 17.1% vs. 11.7%, p
¼ 0.22, respectively). However, the restenosis and TLR rates of 2nd DES were
signiﬁcantly lower than those rates of 1st DES in non-HD patients (19.0% vs.
7.9%, p ¼ 0.015 and 13.9% vs. 5.6%, p ¼ 0.047, respectively). In contrast, those
rates were similar between 2 groups in HD patients (30.2 vs. 32.3%, p ¼ 1.0 and
30.2% vs. 29.0%, p ¼ 1.0, respectively). Table shows quantitative angiographic
outcomes.
Conclusions: The mid-term angiographic results of 2nd DES might be superior to
those of 1st DES in non-HD patients treated with DES implantation following RA.TCT-204
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Background: Differences in enrollment criteria and protocol requirements are thought
to affect patient representation and outcomes from premarket and postmarket
surveillance (PMS). We assessed differences between premarket vs. PMS trials
assessing implantation of the Endeavor-zotarolimus eluting stent (E-ZES).
Methods:We analyzed data from 2132 and 4357 E-ZES treated subjects (ENDEAVOR
premarket and PROTECT PMS trials, respectively). We analyzed differences in 3-year
outcomes and adjusted them for differences in baseline characteristics.
Results: The two groups differed signiﬁcantly in baseline characteristics. However,
the rates of 3-year major adverse cardiac event (MACE), major adverse cardiac and
cerebrovascular event (MACCE) and target vessel failure (TVF), were similar
(12.67% vs. 13.88%, p¼0.191; 11.88% vs. 12.68%, p¼0.369; and 13.81% vs.
13.01%, p¼0.419, respectively). PMS trials had less clinically driven target vessel
revascularizations (CD-TVR, p<0.001) and more myocardial infarctions (MI,
p¼0.005). Differences emerged at 8 moths and immediately post-procedurally,
respectively. After propensity score adjustment, CD-TVR rates no longer differed
signiﬁcantly (HR 0.72, 95% CI 0.51-1.01).Conclusions: Premarket and PMS trials assessing E-ZES implantation had similar
3-year composite outcomes. Differences in CD-TVR were attributed to different
protocol requirements and in MIs to different outcome deﬁnitions. It is yet to be
determined if these settings reﬂect everyday practice.B66 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-205
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Background: Percutaneous coronary intervention (PCI) of moderate and severely
calciﬁed lesions has been described as a predictor of worse outcomes when bare-
metal stents or ﬁrst-generation drug-eluting stents (DES) have been used. Little is
known about the impact of coronary calciﬁcation on outcome after PCI with modern
DES.
Methods: 14,134 patients treated with a biolimus A9-eluting stent with a biodegrad-
able polymer (Nobori, Terumo, Japan) were pooled from 2 all-comer registries
(Nobori-2 and e-Nobori). An independent clinical event committee adjudicated all
adverse events and an independent corelab analyzed baseline and adverse events'
angiograms. Patients were divided into 2 groups based on whether or not PCI was
performed on moderate/severely calciﬁed lesions. Target lesion failure (TLF), deﬁned
as cardiac death, target vessel-related myocardial infarction and target lesion revas-
cularization, and stent thrombosis were assessed at 1 year.
Results: Overall, 4321 patients (30.6%) had moderate/severe coronary calciﬁcation.
Patients with calciﬁed lesions were older and had a higher rate of diabetes mellitus,
hypertension, renal failure, peripheral arterial disease and previous bypass surgery, but
less commonly presented with an acute coronary syndrome. Patients with calciﬁed
lesions more commonly required multivessel treatment and needed longer stents. Pre-
and post- dilatations were more often performed in the calciﬁed lesions group.
Rotational atherectomy or cutting balloons were used in only 5.49%. Preliminary data
at 1-year follow-up (currently available in 9,089 patients) revealed low rates of TLF
and stent thrombosis, but both were signiﬁcantly higher in patients with moderate/
severe calciﬁcation (TLF in 5.03% vs. 2.83%, p<0.001, stent thrombosis in 0.72% vs.
0.34%, p¼0.03). By multivariate analysis, the presence of moderate/severe calciﬁ-
cation was a strong independent predictor of TLF at 1-year (OR1.77, 95%CI 1.23-
2.55, p¼0.002).
Conclusions:Moderate/severe coronary calciﬁcation independently predicts increased
rates of TLF at 1-year after PCI with the biolimus A9-eluting Nobori stent, but overall
stent performance remains excellent and event rates are surprisingly low.
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Background: This study was performed to assess angiographic outcomes of newer
generation drug-eluting stent (NDES) [everolimus-(EES) or resolute zotarolimus-
eluting stents (R-ZES)] versus sirolimus-eluting stents (SES) for long or diabetic
coronary artery disease.
Methods: Patients level data from three randomized trials (Long-DES III, IV and
ESSENCE-DIABETES) were pooled to estimate angiographic efﬁcacy of EES or
R-ZES versus SES. A total of 1,250 patients underwent EES or R-ZES (NDES group,
n¼623) and SES (SES group, n¼627). We evaluated angiographic restenosis after
DES implantation at follow-up duration.
Results: Follow-up angiography was done in 919 patients (73.5%). In-stent (3.0% vs.
4.4%, p¼0.28) and in-segment restenosis (5.0% vs. 5.2%, p¼0.86) was also statis-
tically not different between NDES vs. SES group. In-segment restenosis was similar
between NDES vs. SES group in diabetics (3.9% vs. 6.7%, p¼0.22), > 30 mm long
stent implantation patients (6.9% vs. 6.0%, p¼0.64), and  2.5 mm small vessel
disease (6.3% vs. 8.7%, p¼0.50). However, lesion length > 40 mm showed signiﬁ-
cantly higher angiographic restenosis compared to lesion length  40 mm in both
stents groups (NDES: 10.2% vs. 3.2 %, p¼0.003: SES: 9.0 % vs. 3.9%, p¼0.03).
Conclusions: Newer generation DES showed comparable angiographic outcomes
with SES in patients at high risk of restenosis and effectively reduced angiographic
restenosis across all high risk lesion subsets, but their angiographic efﬁcacies were
attenuated in > 40 mm lesion length in both stent groups.j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
